Maryland State Retirement & Pension System Has $38.35 Million Stake in Eli Lilly and Company (NYSE:LLY)

Maryland State Retirement & Pension System grew its position in Eli Lilly and Company (NYSE:LLY) by 0.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 65,788 shares of the company’s stock after buying an additional 602 shares during the quarter. Eli Lilly and Company accounts for about 0.8% of Maryland State Retirement & Pension System’s portfolio, making the stock its 16th largest holding. Maryland State Retirement & Pension System’s holdings in Eli Lilly and Company were worth $38,349,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in LLY. Simon Quick Advisors LLC grew its holdings in shares of Eli Lilly and Company by 10.5% during the 4th quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock valued at $1,706,000 after purchasing an additional 278 shares during the last quarter. Clear Harbor Asset Management LLC bought a new stake in shares of Eli Lilly and Company during the fourth quarter worth $363,000. Terril Brothers Inc. increased its holdings in shares of Eli Lilly and Company by 113.2% during the fourth quarter. Terril Brothers Inc. now owns 808 shares of the company’s stock worth $471,000 after buying an additional 429 shares in the last quarter. Hartline Investment Corp lifted its stake in shares of Eli Lilly and Company by 1.1% in the 4th quarter. Hartline Investment Corp now owns 21,934 shares of the company’s stock valued at $12,786,000 after acquiring an additional 248 shares during the last quarter. Finally, Commonwealth Equity Services LLC boosted its holdings in shares of Eli Lilly and Company by 5.2% during the 4th quarter. Commonwealth Equity Services LLC now owns 354,565 shares of the company’s stock valued at $206,683,000 after acquiring an additional 17,461 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

LLY has been the subject of several research reports. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. Bank of America lifted their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Cantor Fitzgerald reissued an “overweight” rating and set a $885.00 target price (up from $815.00) on shares of Eli Lilly and Company in a report on Tuesday, April 30th. The Goldman Sachs Group raised their price target on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research note on Thursday, April 11th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 1st. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $757.95.

Eli Lilly and Company Stock Up 1.4 %

Shares of LLY traded up $11.01 during trading hours on Tuesday, hitting $777.69. The stock had a trading volume of 1,948,037 shares, compared to its average volume of 3,077,052. Eli Lilly and Company has a 1-year low of $419.80 and a 1-year high of $800.78. The firm has a market capitalization of $739.12 billion, a P/E ratio of 114.02, a price-to-earnings-growth ratio of 1.45 and a beta of 0.37. The firm has a 50 day simple moving average of $760.96 and a 200-day simple moving average of $673.52. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Monday, May 6th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. During the same quarter last year, the firm posted $1.62 earnings per share. The company’s revenue for the quarter was up 26.0% compared to the same quarter last year. Sell-side analysts predict that Eli Lilly and Company will post 13.82 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 10th. Shareholders of record on Thursday, May 16th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 0.67%. Eli Lilly and Company’s payout ratio is 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.